BLFS Stock Analysis: BioLife Solutions | NASDAQ
Medical Instruments & Supplies | NASDAQ, USA | Market Cap: 1.358m USD | 12M Return: 24% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 23.3M
Qual. Beats: 0
Rev. Trend: -62.8%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
BioLife Solutions, Inc. (BLFS) is a U.S.-based supplier of bioproduction tools and services for the cell and gene therapy (CGT) industry, with operations spanning North America, Europe, the Middle East, and Africa. The companys portfolio spans the workflow, including biopreservation media (HypoThermosol FRS, CryoStor), human platelet lysates for cell expansion, closed-system vials (CellSeal), cryo-compatible containers (CryoCase), automated thawing systems (ThawSTAR), and cloud-connected passive shipping containers (evo). Products serve both research and commercial-scale manufacturing of biologic-based therapies.
The company sells directly and through third-party distributors, serving a sector in which preserving cell viability and maintaining cold-chain integrity are critical because CGT products are inherently temperature-sensitive and often patient-specific, leaving little tolerance for losses during storage, transport, or thawing.
Founded in 1987 and headquartered in Bothell, Washington, BLFS is classified within the Health Care Supplies sub-industry and operates as a small-cap company with a market capitalization of approximately $1.2 billion USD.
- Cell and gene therapy approvals boost biopreservation media demand
- Acquisition integration costs pressure near-term operating margins
- Competition intensifies from Thermo Fisher in bioproduction tools
| Net Income: -10.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.00 > 0.02 and ΔFCF/TA -3.30 > 1.0 |
| NWC/Revenue: 115.2% < 20% (prev 146.0%; Δ -30.82% < -1%) |
| CFO/TA 0.04 > 3% & CFO 17.9m > Net Income -10.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 7.30 > 1.5 & < 3 |
| Outstanding Shares: last quarter (49.2m) vs 12m ago 4.48% < -2% |
| Gross Margin: 63.89% > 18% (prev 50.39%; Δ 13.49% > 0.5%) |
| Asset Turnover: 25.07% > 50% (prev 17.92%; Δ 7.15% > 0%) |
| Interest Coverage Ratio: -4.53 > 6 (EBIT TTM -12.3m / Interest Expense TTM 2.71m) |
| A: 0.29 (Total Current Assets 133.2m - Total Current Liabilities 18.3m) / Total Assets 400.9m |
| B: -0.84 (Retained Earnings -338.5m / Total Assets 400.9m) |
| C: -0.03 (EBIT TTM -12.3m / Avg Total Assets 398.0m) |
| D: 12.98 (Book Value of Equity 372.2m / Total Liabilities 28.7m) |
| Altman-Z'' = 12.55 = AAA |
| DSRI: 1.01 (Receivables 13.1m/9.17m, Revenue 99.8m/70.8m) |
| GMI: 0.79 (GM 50.39% / 63.89%) |
| AQI: 0.98 (AQ_t 0.61 / AQ_t-1 0.63) |
| SGI: 1.41 (Revenue 99.8m / 70.8m) |
| TATA: -0.07 (NI -10.5m - CFO 17.9m) / TA 400.9m) |
| Beneish M = -2.93 (Cap -4..+1) = A |
As of July 11, 2026, the stock is trading at USD 28.18 with a total of 440,630 shares traded. Over the past week, the price has changed by +0.25%, over one month by +5.70%, over three months by +42.76% and over the past year by +24.03%.
Current recommended Stop Loss: 25.50 (which is 9.5% or 2 ATR below the current price).
BioLife Solutions has received a consensus analysts rating of 4.78. Therefore, it is recommended to buy BLFS.
- StrongBuy: 7
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 32.1 | 13.9% |
P/E Forward = 256.4103
P/S = 13.3558
P/B = 3.6883
P/EG = 15.0937
Revenue TTM = 99.8m USD
EBIT TTM = -12.3m USD
EBITDA TTM = -7.46m USD
Long Term Debt = 10.0m USD (estimated: total debt 14.9m - short term 4.82m)
Short Term Debt = 4.82m USD (from shortTermDebt, last quarter)
Debt = 27.2m USD (from shortLongTermDebtTotal, last quarter) + Leases 12.4m
Net Debt = -53.8m USD (calculated: Debt 27.2m - CCE 81.0m)
Enterprise Value = 1.30b USD (1.36b + Debt 27.2m - CCE 81.0m)
Interest Coverage Ratio = -4.53 (Ebit TTM -12.3m / Interest Expense TTM 2.71m)
EV/FCF = -726.8x (Enterprise Value 1.30b / FCF TTM -1.79m)
FCF Yield = -0.14% (FCF TTM -1.79m / Enterprise Value 1.30b)
FCF Margin = -1.80% (FCF TTM -1.79m / Revenue TTM 99.8m)
Net Margin = -10.52% (Net Income TTM -10.5m / Revenue TTM 99.8m)
Gross Margin = 63.89% ((Revenue TTM 99.8m - Cost of Revenue TTM 36.0m) / Revenue TTM)
Gross Margin QoQ = 63.31% (prev 67.48%)
Tobins Q-Ratio = 3.25 (Enterprise Value 1.30b / Total Assets 400.9m)
Interest Expense / Debt = 9.94% (Interest Expense 2.71m / Debt 27.2m)
Taxrate = 4.97% (62.0k / 1.25m)
NOPAT = -11.7m (EBIT -12.3m * (1 - 4.97%)) [loss with tax shield]
Current Ratio = 7.30 (Total Current Assets 133.2m / Total Current Liabilities 18.3m)
Debt / Equity = 0.07 (Debt 27.2m / totalStockholderEquity, last quarter 372.2m)
Debt / EBITDA = 7.21 (negative EBITDA) (Net Debt -53.8m / EBITDA -7.46m)
Debt / FCF = 29.98 (negative FCF - burning cash) (Net Debt -53.8m / FCF TTM -1.79m)
Total Stockholder Equity = 361.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -2.64% (Net Income -10.5m / Total Assets 400.9m)
RoE = -2.91% (Net Income TTM -10.5m / Total Stockholder Equity 361.3m)
RoCE = -3.30% (EBIT -12.3m / Capital Employed (Equity 361.3m + L.T.Debt 10.0m))
RoIC = -3.05% (negative operating profit) (NOPAT -11.7m / Invested Capital 382.5m)
WACC = 10.59% (E(1.36b)/V(1.38b) * Re(10.61%) + D(27.2m)/V(1.38b) * Rd(9.94%) * (1-Tc(0.05)))
Discount Rate = 10.61% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 86.67 | Cagr: 4.27%
[DCF] Fair Price = unknown (Cash Flow -1.79m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.15 | # QB: 0
Revenue Correlation: -62.80 | Revenue CAGR: -18.02% | SUE: 0.25 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.06 | Chg30d=+0.00% | Revisions=+0% | Analysts=1
EPS next Quarter (2026-09-30): EPS=0.07 | Chg30d=+0.00% | Revisions=+0% | Analysts=1
EPS current Year (2026-12-31): EPS=0.25 | Chg30d=+0.00% | Revisions=-25% | GrowthEPS=+91.9% | GrowthRev=+18.4%
EPS next Year (2027-12-31): EPS=0.33 | Chg30d=+13.79% | Revisions=+25% | GrowthEPS=+32.0% | GrowthRev=+18.2%